BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26926380)

  • 1. Correlates of the timed 25 foot walk in a multiple sclerosis outpatient rehabilitation clinic.
    Bethoux FA; Palfy DM; Plow MA
    Int J Rehabil Res; 2016 Jun; 39(2):134-9. PubMed ID: 26926380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does disability level impact the relationship of muscle strength to walking performance in people with multiple sclerosis? a cross-sectional analysis.
    Mañago MM; Callesen J; Dalgas U; Kittelson J; Schenkman M
    Mult Scler Relat Disord; 2020 Jul; 42():102052. PubMed ID: 32240963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.
    Motl RW; Cadavid D; Sandroff BM; Pilutti LA; Pula JH; Benedict RH
    J Neurol Sci; 2013 Dec; 335(1-2):169-73. PubMed ID: 24104065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of patient-reported outcomes of physical activity and accelerometry in people with multiple sclerosis and ambulatory impairment: A cross-sectional study.
    Wanitschek A; Seebacher B; Muehlbacher A; Brenneis C; Ehling R
    Mult Scler Relat Disord; 2024 May; 85():105532. PubMed ID: 38452648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients.
    Phan-Ba R; Calay P; Grodent P; Delrue G; Lommers E; Delvaux V; Moonen G; Nagels G; Belachew S
    NeuroRehabilitation; 2012; 30(4):261-6. PubMed ID: 22672939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximum walking speed in multiple sclerosis assessed with visual perceptive computing.
    Grobelny A; Behrens JR; Mertens S; Otte K; Mansow-Model S; Krüger T; Gusho E; Bellmann-Strobl J; Paul F; Brandt AU; Schmitz-Hübsch T
    PLoS One; 2017; 12(12):e0189281. PubMed ID: 29244874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performed and perceived walking ability in relation to the Expanded Disability Status Scale in persons with multiple sclerosis.
    Langeskov-Christensen D; Feys P; Baert I; Riemenschneider M; Stenager E; Dalgas U
    J Neurol Sci; 2017 Nov; 382():131-136. PubMed ID: 29111007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Turning is an important marker of balance confidence and walking limitation in persons with multiple sclerosis.
    Adusumilli G; Lancia S; Levasseur VA; Amblee V; Orchard M; Wagner JM; Naismith RT
    PLoS One; 2018; 13(6):e0198178. PubMed ID: 29879144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the Six-Spot Step Test as a Measure of Walking Performance in Ambulatory Individuals With Multiple Sclerosis.
    Fritz NE; Jiang A; Keller J; Zackowski KM
    Arch Phys Med Rehabil; 2016 Apr; 97(4):507-512. PubMed ID: 26577146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis.
    Phan-Ba R; Pace A; Calay P; Grodent P; Douchamps F; Hyde R; Hotermans C; Delvaux V; Hansen I; Moonen G; Belachew S
    Neurorehabil Neural Repair; 2011 Sep; 25(7):672-9. PubMed ID: 21436388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The six spot step test: a new measurement for walking ability in multiple sclerosis.
    Nieuwenhuis MM; Van Tongeren H; Sørensen PS; Ravnborg M
    Mult Scler; 2006 Aug; 12(4):495-500. PubMed ID: 16900764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using perceptive computing in multiple sclerosis - the Short Maximum Speed Walk test.
    Behrens J; Pfüller C; Mansow-Model S; Otte K; Paul F; Brandt AU
    J Neuroeng Rehabil; 2014 May; 11():89. PubMed ID: 24886525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.
    Skov CD; Sørensen CB; Thorning M; Lambertsen KL; Frich LH; Jensen HB; Holsgaard-Larsen A; Nielsen HH
    Mult Scler Relat Disord; 2022 Oct; 66():104034. PubMed ID: 35843140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
    Motl RW; Cohen JA; Benedict R; Phillips G; LaRocca N; Hudson LD; Rudick R;
    Mult Scler; 2017 Apr; 23(5):704-710. PubMed ID: 28206828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postural control quantification in minimally and moderately impaired persons with multiple sclerosis: The reliability of a posturographic test and its relationships with functional ability.
    Barbado D; Gomez-Illan R; Moreno-Navarro P; Valero-Conesa G; Reina R; Vera-Garcia FJ
    J Sport Health Sci; 2020 Dec; 9(6):677-684. PubMed ID: 33308819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of Timed 25-Foot Walk Values in Predicting Maximum Walking Distance in Persons with Multiple Sclerosis.
    Alshamrani F; Berger W; Alnajashi H; Payne MWC; Morrow SA
    Int J MS Care; 2020; 22(5):215-218. PubMed ID: 33177957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the impact of fatigue related to walking capacity and perceived ability in persons with multiple sclerosis? A multicenter study.
    Dalgas U; Langeskov-Christensen M; Skjerbæk A; Jensen E; Baert I; Romberg A; Santoyo Medina C; Gebara B; Maertens de Noordhout B; Knuts K; Béthoux F; Rasova K; Severijns D; Bibby BM; Kalron A; Norman B; Van Geel F; Wens I; Feys P
    J Neurol Sci; 2018 Apr; 387():179-186. PubMed ID: 29571860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early outcomes after intrathecal baclofen therapy in ambulatory patients with multiple sclerosis.
    Lee BS; Jones J; Lang M; Achey R; Dai L; Lobel DA; Nagel SJ; Machado AG; Bethoux F
    J Neurosurg; 2018 Oct; 129(4):1056-1062. PubMed ID: 29192855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The timed 25-foot walk in a large cohort of multiple sclerosis patients.
    Kalinowski A; Cutter G; Bozinov N; Hinman JA; Hittle M; Motl R; Odden M; Nelson LM
    Mult Scler; 2022 Feb; 28(2):289-299. PubMed ID: 34100297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
    van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
    Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.